Synexus has further expanded its global presence with the opening of a new in-patient facility in Pretoria, South Africa. Synexus now has a total of four sites in South Africa, which provide access to millions of patients.
The Nyeleti research facility (‘Nyeleti' meaning ‘STAR' in Sotho) has been developed for phase II and III studies that involve 24-hour serial spirometry (lung function), mixed meal tolerance testing, PK visits requiring an overnight stay or when infusion is required. This new site will support the existing Synexus clinical trial centers in Pretoria and Mamelodi.
The facility includes an in-patient ward as well as a secure, temperature-controlled dispensing unit designed to manage supplies according to ICH, GCP and national guidelines. It also houses emergency and other resuscitative equipment, a transit laboratory and food preparation area and has ambulance support.
“Synexus recognizes the vital role South Africa has to play in global clinical trials and continues to invest in the region,” said Dr. Christophe Berthoux, CEO of Synexus. “In addition to providing access to a large patient pool, many of whom are treatment naive, the medical infrastructure and training is of a very high standard. There is also a high public awareness of the benefits of clinical trials, which speeds up recruitment and overcomes the lengthy regulatory process. These are all key factors in ensuring the success of a clinical trial."
Dr. Sanet Aspinall, managing director of Synexus South Africa, said, "We are well positioned to continue our success as the leading professional investigator organization in South Africa that meets, and often exceeds, our clients' needs in conducting phase II-IV studies.”
